Edward Randolph

Mr. Randolph served as Vice President of Manufacturing from 2007 to 2016. From 2003 to 2007, he was Director of Manufacturing Engineering at the electrophysiology division of Boston Scientific Corp, where he was instrumental in the execution of remedial process validation in response to their 2006 FDA Warning Letter. From 2001 to 2003, Mr. Randolph was the Director of Manufacturing Engineering at Cygnus, Inc., where he prepared the manufacturing operation to support the market launch of the GlucoWatch, a novel non-invasive transdermal drug delivery system. Prior positions included 7 years at Ventritex, an implantable cardiac defibrillator company where he facilitated the relocation of manufacturing following the acquisition of that company by Pacesetter. He received his Master of Science in Engineering from Stanford University and his Bachelor of Science in Architecture from Massachusetts Institute of Technology.